Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction.
BACKGROUND
Pro- and anti-inflammatory cytokines play a major role in the development of acute myocardial infarction (AMI). This paper tests the hypothesis that atorvastatin may attenuate the severity of myocardial ischemic injury by restoring the balance between pro-inflammatory and anti-inflammatory mediators.


METHODS
Sixty adult male albino rats were used. Experimental AMI was induced by subcutaneous injection of isoprenaline. Atorvastatin was given for five days, then, it was combined with isoprenaline in the last two days of treatment protocol. Rats without any treatment were used as controls. Rats were subjected to ECG tracing, assessment of Creatine phosphokinase (CPK) and CPK-MB, measurements of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-10 (IL-10), and plasminogen activator inhibitor-1 (PAI-1).


RESULTS
Induction of AMI by isoprenaline resulted in a significant elevation of ST segment, elevation of CPK and CPK-MB. CRP, TNF-alpha and plasma PAI-1 were significantly elevated in the AMI rats compared to the control groups. On the other hand, the level of the anti-inflammatory cytokine IL-10 was significantly reduced. Treatment with atorvastatin prior to induction of AMI was associated with a significant reduction of serum CRP, TNF-alpha, plasma PAI-1 and an increase of serum IL-10.


CONCLUSIONS
This study suggests the usefulness of atorvastatin as an attenuating agent against AMI. Atorvastatin restores the balance between the pro-inflammatory and the anti-inflammatory mediators and modulates the fibrinolysis by reducing the levels of PAI-1.
Tawfik
Mona K
MK
Department of Pharmacology, School of Pharmacy, Suez Canal University, Ismailia, Egypt. dmon_kamal@yahoo.com
Ghattas
Maivel H
MH
Abo-Elmatty
Dina M
DM
Abdel-Aziz
Nagla A
NA
D000208:Acute Disease; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000032:analysis; D004562:Electrocardiography / Q000187:drug effects; D006538:Heptanoic Acids / Q000494:pharmacology*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D016753:Interleukin-10 / Q000097:blood; D008297:Male; D009203:Myocardial Infarction / Q000276:immunology*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011758:Pyrroles / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000893:Anti-Inflammatory Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017395:Plasminogen Activator Inhibitor 1; D011758:Pyrroles; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D002097:C-Reactive Protein; D000069059:Atorvastatin